Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Completed × Pluvicto × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Recruiting 2 Not yet recruiting 2 Active not recruiting 2 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Cyclophosphamide 251 Cisplatin 240 Radiotherapy 217 Paclitaxel 206 Docetaxel 192 Fluorouracil 187 Carboplatin 186 Doxorubicin 185 Dexamethasone 144 Gemcitabine 130 Vincristine 122 Capecitabine 110 Etoposide 109 Prednisone 108 Leucovorin 104 Bevacizumab 101 Methotrexate 100 Rituximab 94 Cytarabine 93 Filgrastim 82 Trastuzumab 81 Oxaliplatin 75 pembrolizumab 66 Pemetrexed 59 Drug Therapy 59 Tamoxifen 58 Epirubicin 53 Chemotherapy, Adjuvant 51 Irinotecan 50 Granulocyte Colony-Stimulating Factor 50

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03511664 2025-01-13

VISION

Endocyte

Phase 3 Completed

861 enrolled 39 charts 1 FDA

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡